Medications for CDKL5 Deficiency Disorder

CDKL5 Deficiency Disorder (CDD) is a serious and rare form of genetic epilepsy.

CDD is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome. The CDKL5 gene produces a protein that is important for normal brain development and function.

CDD is characterized by early-onset, difficult-to-control seizures and severe neuro-developmental impairment. Most children affected by CDD cannot walk, talk, or feed themselves. 

Ztalmy (ganaxolone) is the first treatment approved specifically for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). Ztalmy works by exhibiting anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABA_A receptors.